Krystal Biotech, Inc. (KRYS) Tops Q2 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KRYS Hot Sheet
Join SI Premium – FREE
Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.29, $0.07 better than the analyst estimate of $1.22. Revenue for the quarter came in at $96.04 million versus the consensus estimate of $92.24 million.
For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
- CompX International (CIX) Reports Q3 EPS of $0.44
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
